

Drug and Therapeutics Committee – Minutes – approved

Date / Time	8 th October 2015
Venue	The Committee Room, Alderson House, HRI
Chair	Prof M Lind, Vice Chair, Professor of Oncology
Notes / Action Points	Mrs Wendy Hornsby, Senior Pharmacy Technician.
Quorate: Yes / No	Yes

Attendance	Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services Mr P O'Brien, Deputy Chief Pharmacist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Dr O Ogunbambi, Consultant Rheumatologist Mr K McCorry, Pharmaceutical Advisor, ER CSU Ms S Ditchburn, Pre Reg Pharmacist (Guest) Mr T Maund, Pre Reg Pharmacist (Guest) Ms K Mubanga, Pre Reg Pharmacist (Guest) Ms M Papakosta, Pre Reg Pharmacist (Guest)
Apologies	Mrs C Grantham, Medicines Management Nurse Dr H Klonin, Consultant Paediatrician Mrs J Lyon, Head of Medicines Management, North Yorks and Humber CSU Prof A Morice, Chair, Professor of Respiratory Medicine Dr E Williamson, Consultant Microbiologist

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2015.10.01	Apologies	As above.					
2015.10.02	Declarations of Interest	None.	Noted	No further action			10/15
2015.10.03	Minutes of the previous meeting	The minutes were accepted as a true record.	Noted	No further action			10/15
2015.10.04	Action Tracker	<p>Correspondence Received Pembrolizumab is now licensed but does not have NICE approval, therefore no longer require new product request</p> <p>TA344 Ofatumumab WH has added to formulary as "pending application/available via chairs approval"</p> <p>New Product Requests AM has written to applicants and WH has updated formulary</p> <p>New Product Request SG has written to ophthalmology regarding cyclosporine eye drops/ointment. Ophthalmology would still like to keep the unlicensed 2 % product as an option for severe ocular surface disease, where 0.1% cannot be used.</p> <p>Omalizumab SG has written to Dr Gordins & WH has</p>	<p>Noted</p> <p>Noted</p> <p>Action Complete</p> <p>Action Complete.</p> <p>Action Complete</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>WH to update lists</p> <p>No further action</p>		<p></p> <p></p> <p></p> <p>10/15</p> <p></p>	<p>10/15</p> <p>10/15</p> <p>10/15</p> <p></p> <p>10/15</p>

		updated formulary					
		NICE Guidance – TA345 Naloxogel Has been added to formulary for chairs approval only until submission received.	Action complete	No further action			10/15
		NICE Guidance – TA347 Nintedanib Application is being written.	Action complete	No further action			10/15
		Opioid Conversion Chart SG has written to palliative care and has received feedback from interface pharmacist as chart does not mirror current HERPC guidance. SG still awaiting further feedback from palliative care and will feedback next time.	SG will feedback comments at next D&T	SG to feed back at next D&T meeting	SG	11/15	
		Opioid Conversion Chart WH to arrange for link to be added to intranet once final version approved.	Add to intranet once approved	Ongoing, as above	WH	12/15	
		Update on Botulinum Toxin (Xeomin) SG has written to Dr Salawu to inform him Xeomin has been approved for his use	Action Complete	No further action			10/15
		Correspondence Received – TA47 Tlrofiban has been added to formulary	Action complete	No further action			10/15
		Correspondence Received – Psoriasis Treatment Flow Chart – Dr S Walton SG has written to Dr Walton, Dr Zamman & Yvonne Skelly to ask for a revised chart	Action complete	No further action			10/15
		AOB SG has spoken to PK and advised that Iron (III) Isomaltoside (Diafer) will be added to formulary as a line extension.	Action complete	No further action			10/15
		AOB					

		<p>Disofrol – POB is still trying to source an alternative</p> <p>AOB Borderline Substance Paper POB has met with theatre manager, is preparing a paper and will bring to committee next month for discussion</p>	<p>Ongoing</p> <p>POB will write paper and bring back to next D&T for discussion</p>	<p>Add to agenda for next D&T meeting</p>	<p>POB</p> <p>POB/WH</p>	<p>11/15</p> <p>11/15</p>	
2015.10.05	New Product Requests	<p>AREDS 2 – Miss L Downey The AREDS 2 formulation applied for on application is currently unavailable in the UK. Pharmacy has reviewed information for Preservision Lutein (nearest available preparation). The various subgroups of the AREDS2 clinical trial demonstrated that the differing preparations had similar efficacy.</p> <p>AdCal D3 Caplets – Dr E Baguley Committee approved in principal the need for a caplet formulation to be available as an alternative to a chewable tablet. POB will inform which preparation is to be used after contracts are agreed next month.</p> <p>Toujeo – Insulin Glargine 300units/ml pre-filled pen – Dr Mohammed/Endocrinology team This product is only available as a prefilled pen, therefore avoiding the risks associated with being 200 units/ml strength. Approved for use, but the committee were unclear which patients would go onto this strength.</p>	<p>Preservision Lutein approved, as an alternative to the original Preservision (AREDS) formula</p> <p>Pharmacy to prepare prescribing guideline in due course</p> <p>Approved</p>	<p>ML to write to Miss Downey to ask if this formulation would be acceptable.</p> <p>POB to feed back regarding contracts</p> <p>ML to write to Dr Mohammed and ask for clarification of patient cohort</p>	<p>ML</p> <p>POB</p> <p>ML</p>	<p>11/15</p> <p>Nov 15</p> <p>Nov 15</p>	

2015.10.06	NICE Guidance	<p>August 2015</p> <ul style="list-style-type: none"> • NG17 <i>Type 1 diabetes in adults: diagnosis and management</i> • NG 18 <i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</i> • NG 19 <i>Diabetic foot problems: prevention and management</i> • TA352 <i>Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy</i> • TA353 <i>Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)</i> • TA354 <i>Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism</i> <p>September 2015</p> <ul style="list-style-type: none"> • NG20 <i>Coeliac disease: recognition, assessment and management</i> • NG21 <i>Home care: delivering personal care and practical support to older people living in their own homes</i> • TA355 <i>Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation</i> • TA356 <i>Ruxolitinib for treating polycythaemia vera (terminated appraisal)</i> 	<p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Edoxaban not currently on formulary</p> <p>Noted</p> <p>Noted</p> <p>As above</p> <p>Noted</p>	<p>Edoxaban to be added to formulary as pending application</p>	<p>WH</p>	<p>11/15</p>	<p>10/15</p>
2015.10.07	MHRA Drug Safety update September 2015	<p>Noted</p> <p>KMc said that PPI will be mentioned in the next medicines management newsletter to highlight to GP's.</p>	<p>Noted</p>	<p>No further action</p>			<p>10/15</p>

2015.10.08	IBD Guideline	Pathway to demonstrate use of biologicals in treatment Approved, with all drugs already on formulary	Noted	No further action			10/15
2015.10.09	CCG Representation on D&T	Recently both prescribing leads for Hull and ER have stepped down from post. Both CCG's are in process of appointing new prescribing leads. The CSU have advised that the new prescribing leads would not be able to attend D&T as they would be prioritising HERPC.	ML to discuss with AM as primary care input is greatly valued by D&T	ML & AM to agree whether to write to CCG	ML/AM	11/15	
2015.10.11	Minutes from Safe Medication Practice Committee	June 2015 July 2015	DC highlighted some of the recent issues discussed	No further action			10/15
2015.10.12	Correspondence Received	Duraphat 5000 Toothpaste Royal College of Orthodontics National Guidelines for restorative dentistry for radiotherapy patients recommends use of this product alongside fluoride mouthwash. Duraphat Toothpaste 2800 ppm (Sodium Fluoride 0.619%) was already formulary, but the 5000ppm strength was not. Branded Generic Oral Contraceptives Millinette 20/75 Tablets Millinette 30/75 Tablets CHCP have agreed to switch over to the above generic versions of oral contraceptives. Haloperidol Shortage The trust has been made aware that there is a national shortage of haloperidol injections. The trust currently has approximately three weeks supply left. Pharmacy department are currently drafting guidance alongside CHCP and HFT.	Duraphat 5000 toothpaste and fluoride mouthwash to be added to formulary Change HEY formulary to fit with CHCP choices Pharmacy to circulate guidance on how to manage the shortage	WH to add 5000 ppm strength to formulary WH to amend formulary	WH WH POB	11/15 11/15 11/15	

		Ulipristal D&T approved for use pre op for intra uterine fibroids, licence has now been extended to include treatment of fibroids in women who choose to avoid surgery.	No need for new application to D&T to be made. Further discussion to take place at HERPC	WH to add to HERPC agenda	WH	11/15	
2015.10.12	Chairs Approvals	<ul style="list-style-type: none"> IV Omeprazole 	Noted	No further action			10/15
2015.10.13	Issues to escalate to Operational Quality Committee	No issues to escalate					10/15
2015.10.14	Any other Business	Midodrine is now licensed for treatment of orthostatic hypotension. The Trust already used an unlicensed supply for this indication. Pregabalin Pfizer have lost court case to protect Lyrica licence for treatment of neuropathic pain but it is anticipated they will appeal. Until final ruling trust will continue to follow the NHSE prescribing guidance, already circulated.	Remove from unlicensed list and add to formulary Noted	WH to update formulary No further action		11/15	10/15
2015.10.15	Date and Time of Next Meeting	Thursday 12 th November 2015, 8.15am – 9.30am. The Board Room, Alderson House, HRI					